• Company to address unmet medical needs in the field of rare metabolic disorders
  • Exclusive IP licensed from Leiden University and Amsterdam UMC
  • Senior industry R&D leader Olivier Morand appointed as Chief Executive Officer and
    member of the Board of Directors
  • BioGeneration Ventures founding investor

Leiden, The Netherlands, July 23th, 2018 – Azafaros, a biotech company established in Leiden in the
Netherlands, focusing on the development of new therapies in the field of rare metabolic disorders,
today announced the closing of a seed financing round. BioGeneration Ventures (BGV) is the founding
investor.

Rare metabolic disorders such as lysosomal storage disorders (LSDs) represent a broad class of severe
and sometimes life-threatening inherited diseases, presenting significant unmet medical needs, with
only few approved therapies. With its proprietary small molecule compounds, Azafaros will
concentrate on new treatments for patients suffering from LSDs and LSD-related diseases. These
compounds interfere with the metabolism of glycolipids that is disturbed in these patients and are
intended to counteract the underlying pathological effects.

Azafaros holds an exclusive license from Leiden University and Amsterdam UMC (location AMC) to a
library of novel compounds and patents that were discovered by Professor Hans Aerts and his coworkers
at Amsterdam UMC and Leiden University. Through a broad research collaboration Azafaros
will benefit from the vast experience of the group led by Professor Hans Aerts to progress the
technology.

Olivier Morand, Ph.D. and IMD alumnus, is joining Azafaros as Chief Executive Officer (CEO) and
member of the Board of Directors. Olivier Morand, a senior leader in pharma strategic development
for early- and late-phase products, brings many years of hand-on experience and know-how in rare
metabolic disorders and orphan drugs. He has a very strong industry track record most recently at
Idorsia Pharmaceuticals, and before that at Actelion Pharmaceuticals and Hoffmann-La Roche. In his
early career, he held various roles in academic institutions such as INSERM Paris, the University of
Wisconsin Madison, the Hadassah Medical School Jerusalem and the Mount Sinai Medical School New
York. With this, Olivier Morand brings a broad scientific, clinical and regulatory experience as well as
business insights to the Azafaros team.

Olivier Morand, CEO, says: “I feel very privileged to lead Azafaros I anticipate that with our focused
efforts the company will be able to develop high performing drugs out of the Leiden University and
Amsterdam UMC compound library, supported by a solid patent position, and based on strong scientific
rationale and sound clinical approaches.”

Edward van Wezel, managing partner at BGV and member of the Board of Directors, comments: “We
are very excited to be able to support the development of new treatment modalities for LSDs with a
founding team that has strong scientific and business experience in a field with clear unmet medical
needs. We strongly believe that these new compounds have the potential to offer better clinical
outcome for patients in the future.”

About Azafaros

Azafaros is a spin-off from Leiden University and Amsterdam UMC (location AMC). The company aims
at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal
storage disorders through oral administration of aza-sugar compounds. These novel, very promising
agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are
exclusively licensed to Azafaros.

For further information

Azafaros B.V.
Email : info@azafaros.com
Tel : +31 (0) 35 699 30 00
www.azafaros.com